Treatment-related cardiovascular toxicity in long-term survivors of testicular cancer
Article Category: Review
Publié en ligne: 19 avr. 2016
Pages: 221 - 227
Reçu: 04 févr. 2016
Accepté: 14 févr. 2016
DOI: https://doi.org/10.1515/raon-2016-0021
Mots clés
© 2017 Jasenka Gugic, Lorna Zadravec Zaletel, Irena Oblak
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Backgrounds
Testicular cancer is the most common malignancy in young men. Considering increasing incidence, exceptionally high cure rate, as well as long life expectancy, assessment of long term toxicity in testicular cancer survivors is of great importance. In the last decades a major effort has been made in order to reduce toxicity of treatment, while maintaining its high effectiveness.
Conclusions
Actual knowledge on treatment toxicity is based on outdated treatment modalities. Hopefully, modern treatment modalities could reduce toxicity, but, there is no firm confirmation for that at the moment, as data dealing with late sequelae of modern treatment of testicular cancer are not available yet due to the short period of observation. The life-threatening cardiovascular toxicity in testicular cancer survivors is major complication of platinum-based chemotherapy, mediastinal radiotherapy and even subdiaphragmatic radiotherapy.